Menu Back toTOPIC-2-SESSION-6-Reporting-Requirements-in-Special-Situations-in-the-Post-authorisation-Phase-and-Case-Studies
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Joint MHRA/DIA Excellence in Pharmacovigilance
TOPIC 2 SESSION 6: Reporting Requirements in Special Situations in the Post-authorisation Phase and Case Studies
Gaby L. Danan, MD, PhD
- Pharmacovigilance Expert
- GLD, France
- Head of Vigilance Operations, Safety & Surveillance
- Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Reporting Requirements in Special Situations in the Post-authorisation Phase and Case Studies
- Head of Vigilance Development
- Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom